Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy

Joo Yong Lee, Dae Hun Lee, Nam Hoon Cho, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Seung Choul Yang, Kang Su Cho

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To analyze overall survival (OS), prostate cancer (PCa)-specific survival (PCaSS), and non-PCaSS according to the Charlson Comorbidity Index (CCI) after radical prostatectomy (RP) for PCa. Materials and Methods: Data from 336 patients who had RP for PCa between 1992 and 2005 were analyzed. Data included age, pre-operative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage. Pre-existing comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0, ≥1). Results: The mean age of patients was 64.31±6.12 years. The median PSA value (interquartile range, IQR) was 11.30 (7.35 and 21.02) ng/mL with a median follow-up period (IQR) of 96.0 (85.0 and 121.0) months. The mean CCI was 0.28 (0-4). Five-year OS, PCaSS, and non-PCaSS were 91.7%, 96.3%, and 95.2%, respectively. Ten-year OS, PCaSS, and non-PCaSS were 81.9%, 92.1%, and 88.9%, respectively. The CCI had a significant influence on OS (p=0.022) and non-PCaSS (p=0.008), but not on PCaSS (p=0.681), by log-rank test. In multivariate Cox regression analysis, OS was independently associated with the CCI [hazard ratio (HR)=1.907, p=0.025] and Gleason score (HR=2.656, p<0.001). PCaSS was independently associated with pathologic N stage (HR=2.857, p=0.031), pathologic T stage (HR=3.775, p=0.041), and Gleason score (HR=4.308, p=0.001). Non-PCaSS had a significant association only with the CCI (HR=2.540, p=0.009). Conclusion: The CCI was independently associated with both OS and non-PCaSS after RP, but the CCI had no impact on PCaSS. The comorbidities of a patient should be considered before selecting RP as a curative modality for PCa.

Original languageEnglish
Pages (from-to)316-323
Number of pages8
JournalYonsei medical journal
Volume55
Issue number2
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Prostatectomy
Comorbidity
Prostatic Neoplasms
Survival
Neoplasm Grading
Prostate-Specific Antigen
Survival Analysis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{a9ec53bdc8cf46ae8557c67291c0ec76,
title = "Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy",
abstract = "Purpose: To analyze overall survival (OS), prostate cancer (PCa)-specific survival (PCaSS), and non-PCaSS according to the Charlson Comorbidity Index (CCI) after radical prostatectomy (RP) for PCa. Materials and Methods: Data from 336 patients who had RP for PCa between 1992 and 2005 were analyzed. Data included age, pre-operative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage. Pre-existing comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0, ≥1). Results: The mean age of patients was 64.31±6.12 years. The median PSA value (interquartile range, IQR) was 11.30 (7.35 and 21.02) ng/mL with a median follow-up period (IQR) of 96.0 (85.0 and 121.0) months. The mean CCI was 0.28 (0-4). Five-year OS, PCaSS, and non-PCaSS were 91.7{\%}, 96.3{\%}, and 95.2{\%}, respectively. Ten-year OS, PCaSS, and non-PCaSS were 81.9{\%}, 92.1{\%}, and 88.9{\%}, respectively. The CCI had a significant influence on OS (p=0.022) and non-PCaSS (p=0.008), but not on PCaSS (p=0.681), by log-rank test. In multivariate Cox regression analysis, OS was independently associated with the CCI [hazard ratio (HR)=1.907, p=0.025] and Gleason score (HR=2.656, p<0.001). PCaSS was independently associated with pathologic N stage (HR=2.857, p=0.031), pathologic T stage (HR=3.775, p=0.041), and Gleason score (HR=4.308, p=0.001). Non-PCaSS had a significant association only with the CCI (HR=2.540, p=0.009). Conclusion: The CCI was independently associated with both OS and non-PCaSS after RP, but the CCI had no impact on PCaSS. The comorbidities of a patient should be considered before selecting RP as a curative modality for PCa.",
author = "Lee, {Joo Yong} and Lee, {Dae Hun} and Cho, {Nam Hoon} and Rha, {Koon Ho} and Choi, {Young Deuk} and Hong, {Sung Joon} and Yang, {Seung Choul} and Cho, {Kang Su}",
year = "2014",
month = "3",
day = "1",
doi = "10.3349/ymj.2014.55.2.316",
language = "English",
volume = "55",
pages = "316--323",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy. / Lee, Joo Yong; Lee, Dae Hun; Cho, Nam Hoon; Rha, Koon Ho; Choi, Young Deuk; Hong, Sung Joon; Yang, Seung Choul; Cho, Kang Su.

In: Yonsei medical journal, Vol. 55, No. 2, 01.03.2014, p. 316-323.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy

AU - Lee, Joo Yong

AU - Lee, Dae Hun

AU - Cho, Nam Hoon

AU - Rha, Koon Ho

AU - Choi, Young Deuk

AU - Hong, Sung Joon

AU - Yang, Seung Choul

AU - Cho, Kang Su

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Purpose: To analyze overall survival (OS), prostate cancer (PCa)-specific survival (PCaSS), and non-PCaSS according to the Charlson Comorbidity Index (CCI) after radical prostatectomy (RP) for PCa. Materials and Methods: Data from 336 patients who had RP for PCa between 1992 and 2005 were analyzed. Data included age, pre-operative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage. Pre-existing comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0, ≥1). Results: The mean age of patients was 64.31±6.12 years. The median PSA value (interquartile range, IQR) was 11.30 (7.35 and 21.02) ng/mL with a median follow-up period (IQR) of 96.0 (85.0 and 121.0) months. The mean CCI was 0.28 (0-4). Five-year OS, PCaSS, and non-PCaSS were 91.7%, 96.3%, and 95.2%, respectively. Ten-year OS, PCaSS, and non-PCaSS were 81.9%, 92.1%, and 88.9%, respectively. The CCI had a significant influence on OS (p=0.022) and non-PCaSS (p=0.008), but not on PCaSS (p=0.681), by log-rank test. In multivariate Cox regression analysis, OS was independently associated with the CCI [hazard ratio (HR)=1.907, p=0.025] and Gleason score (HR=2.656, p<0.001). PCaSS was independently associated with pathologic N stage (HR=2.857, p=0.031), pathologic T stage (HR=3.775, p=0.041), and Gleason score (HR=4.308, p=0.001). Non-PCaSS had a significant association only with the CCI (HR=2.540, p=0.009). Conclusion: The CCI was independently associated with both OS and non-PCaSS after RP, but the CCI had no impact on PCaSS. The comorbidities of a patient should be considered before selecting RP as a curative modality for PCa.

AB - Purpose: To analyze overall survival (OS), prostate cancer (PCa)-specific survival (PCaSS), and non-PCaSS according to the Charlson Comorbidity Index (CCI) after radical prostatectomy (RP) for PCa. Materials and Methods: Data from 336 patients who had RP for PCa between 1992 and 2005 were analyzed. Data included age, pre-operative prostate-specific antigen (PSA), prostate volume, clinical stage, and pathologic stage. Pre-existing comorbidities were evaluated by the CCI, and patients were classified into two CCI score categories (0, ≥1). Results: The mean age of patients was 64.31±6.12 years. The median PSA value (interquartile range, IQR) was 11.30 (7.35 and 21.02) ng/mL with a median follow-up period (IQR) of 96.0 (85.0 and 121.0) months. The mean CCI was 0.28 (0-4). Five-year OS, PCaSS, and non-PCaSS were 91.7%, 96.3%, and 95.2%, respectively. Ten-year OS, PCaSS, and non-PCaSS were 81.9%, 92.1%, and 88.9%, respectively. The CCI had a significant influence on OS (p=0.022) and non-PCaSS (p=0.008), but not on PCaSS (p=0.681), by log-rank test. In multivariate Cox regression analysis, OS was independently associated with the CCI [hazard ratio (HR)=1.907, p=0.025] and Gleason score (HR=2.656, p<0.001). PCaSS was independently associated with pathologic N stage (HR=2.857, p=0.031), pathologic T stage (HR=3.775, p=0.041), and Gleason score (HR=4.308, p=0.001). Non-PCaSS had a significant association only with the CCI (HR=2.540, p=0.009). Conclusion: The CCI was independently associated with both OS and non-PCaSS after RP, but the CCI had no impact on PCaSS. The comorbidities of a patient should be considered before selecting RP as a curative modality for PCa.

UR - http://www.scopus.com/inward/record.url?scp=84894282962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894282962&partnerID=8YFLogxK

U2 - 10.3349/ymj.2014.55.2.316

DO - 10.3349/ymj.2014.55.2.316

M3 - Article

C2 - 24532498

AN - SCOPUS:84894282962

VL - 55

SP - 316

EP - 323

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -